Clinical Trial Search

Primary: Circulating Levels (Plasma Concentration) of Omeprazole Prior to Treatment With Luliconazole Cream 1% — 0; 0; 23.67; 196.30 ng/mL

Primary: Circulating Plasma Concentration of Luliconazole at Day 7 (Pre-Dose) — 4.63; NA nanograms/milliliter (ng/mL)

Primary: Percentage of Participants With Satisfactory Relief of Non-ulcer Dyspepsia Symptoms — 71; 34; 82; 56 percentage of participants

Primary: Measurement of Circulating Plasma Levels of Luliconazole in Participants Who Had Tinea Pedis: Maximum Observed Plasma Concentration (Cmax) of Luliconazole — 3.27…

Primary: Vaccine Efficacy — 4; 2; 4; 0 Participants

Primary: Number of Participants With Implant-Related Serious Adverse Events — 0 Participants

Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants

Primary: Pharmacodynamics (PD): Change From Baseline in Mean 24-hour Systolic Blood Pressure (SBP) — 13.81; 12.17; 13.63; 11.42 Millimeters of mercury (mmHg)

Primary: Number of Participants With Adverse Pregnancy Outcomes — 45; 39 Participants — p=<0.05

Primary: Distribution Volume Ratio (DVR) — 1.30; 1.39; 1.26; 1.34 Distribution Volume Ratio (DVR) — p=<0.02

Primary: Adherence to Diet - Use of Dietary Information — 3.0; 3.3; 2.7; 3.3 score on a scale — p=.045

Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAE) Over the Treatment Period in Part 1 and Part 2 — 37.5; 62.5; 87.5; 100.0 Percentage of…

Primary: Depressive Symptoms Collected With the Patient Health Questionnaire-9 (PHQ-9) — 6.63; 8.68 score on a scale — p=<0.001

Primary: Disease Control Rate — 18; 8 Participants

Primary: Number of Participants With Non-uniform Bowel Lumen Opacification at CT Imaging — 140; 73; 68 Participants